CytomX Therapeutics Files Q1 2025 10-Q
Ticker: CTMX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, licensing, financing, biotech
Related Tickers: AMGN, BMY, MRNA
TL;DR
CytomX Q1 2025 10-Q filed. Updates on Amgen, BMS deals. Warrant with Bvf Partners noted.
AI Summary
CytomX Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its ongoing collaborations, including agreements with Amgen Inc. and Bristol Myers Squibb Company, with specific dates for these arrangements noted. The filing also mentions a Pre-Funded Warrant with Bvf Partners LP, dated July 2023, and details on employee severance as of March 31, 2025.
Why It Matters
This filing provides investors with an update on CytomX's financial health and ongoing strategic partnerships, crucial for understanding the company's future development and revenue potential.
Risk Assessment
Risk Level: medium — The company's reliance on collaborations and potential future financing needs present inherent risks.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for this filing.)
- 2025-01-01 — Reporting Period Start Date (Indicates the start of the fiscal quarter for this filing.)
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Filer
- Amgen Inc. (company) — Collaboration partner
- Bristol Myers Squibb Company (company) — Collaboration partner
- Bvf Partners LP (company) — Pre-funded warrant holder
- 2025-03-31 (date) — Reporting period end date
- 2025-01-01 (date) — Reporting period start date
- 2017-09-29 (date) — Amgen collaboration agreement date
- 2014-07-07 (date) — Bristol Myers Squibb collaboration agreement date
- 2023-07 (date) — Bvf Partners LP pre-funded warrant date
FAQ
What is the status of CytomX's collaborations with Amgen Inc. and Bristol Myers Squibb Company as of March 31, 2025?
The filing references collaboration and license agreements with Amgen Inc. (dated 2017-09-29) and Bristol Myers Squibb Company (dated 2014-07-07), and indicates ongoing activity within these arrangements during the period 2025-01-01 to 2025-03-31.
What is the significance of the Pre-Funded Warrant mentioned in the filing?
A Pre-Funded Warrant was issued to Bvf Partners LP in July 2023, and its terms are relevant to the company's capital structure as of March 31, 2025.
Are there any significant employee-related financial events reported for the quarter ending March 31, 2025?
Yes, the filing mentions employee severance costs in relation to us-gaap:EmployeeSeveranceMember as of March 31, 2025.
What was the company's retained earnings as of the end of the previous fiscal year?
The company's retained earnings as of December 31, 2024, are noted as us-gaap:RetainedEarningsMember.
Does the filing mention any other significant partnerships or agreements during the reporting period?
Yes, the filing references agreements with ModernaTx Inc. and a Transition Agreement, both active during the period 2025-01-01 to 2025-03-31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding CytomX Therapeutics, Inc. (CTMX).